Identification of β‑catenin target genes in colorectal cancer by interrogating gene fitness screening data
- Haomin Zhao
- Liang He
- Dexin Yin
- Bin Song
Affiliations: Department of Vascular Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Gastrointestinal Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
- Published online on: August 6, 2019 https://doi.org/10.3892/ol.2019.10724
Copyright: © Zhao
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
β‑catenin regulates its target genes which are associated with proliferation, differentiation, migration and angiogenesis, and the dysregulation of Wnt/β‑catenin signaling facilitates hallmarks of colorectal cancer (CRC). Identification of β‑catenin targets and their potential roles in tumorigenesis has gained increased interest. However, the number of identified targets remains limited. The present study implemented a novel strategy, interrogating gene fitness profiles derived from large‑scale RNA interference and CRISPR‑CRISPR associated protein 9 screening data to identify β‑catenin target genes in CRC cell lines. Using these data sets, pair wise gene fitness similarities were determined which highlighted a total of 13 genes whose functions were highly correlated with β‑catenin. It was further demonstrated that the expression of these genes were altered in CRC, illustrating their potential roles in the progression of CRC. The present study further demonstrated that these targets could be used to predict disease‑free survival in CRC. In conclusion, the findings provided novel approaches for the identification of β‑catenin targets, which may become prognostic biomarkers or drug targets for the management of CRC.